Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ian C. Mortimer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 364
- Beta
- 0.60
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 35.85
Financials
Revenue
$0.00-100.0%Net Income
$-110.74MEBITDA
$-110.76MFree Cash Flow
$-95.67MEPS (diluted)
$-1.11Shares Outstanding (diluted)
99.61M+552.4%Operating Expenses
$123.16MCash & Debt
$930.69MRevenue by Segment (annual)
$9.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.50M | $-345.91M | $-4.36 |
| 2024 | $0.00 | $-234.33M | $-3.01 |
| 2023 | $0.00 | $-182.39M | $-2.73 |
| 2022 | $9.43M | $-125.37M | $-2.06 |
| 2021 | $18.44M | $-78.88M | $-1.77 |
| 2020 | $32.17M | $-28.84M | $-0.83 |
| 2019 | $6.83M | $-41.59M | $-1.54 |
| 2018 | $0.00 | $-34.50M | $-1.78 |
| 2017 | $311.0K | $-30.70M | $-1.71 |
| 2016 | $1.80M | $-23.00M | $-1.48 |
| 2015 | $15.58M | $-15.75M | $-1.10 |
| 2014 | $28.37M | $13.02M | $0.94 |
| 2013 | $27.36M | $12.03M | $0.42 |
| 2012 | $14.31M | $-4.30M | $-3.23 |
Valuation
XENEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+25.00%Social Signal Score
Mentions (15)
- Newszacks.com·4d ago·Neutral
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
View source ↗ - Newsmarketbeat.com·22d ago·Negative
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
View source ↗ - Newsbusinesswire.com·27d ago·Negative
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsprnewswire.com·27d ago·Negative
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept.
View source ↗ - Newsseekingalpha.com·27d ago·Neutral
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential, but I think epilepsy still provides a viable foundation for the bull case. XENE's liquid balance sheet should help it fund the remaining regulatory work and launch preparations.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
View source ↗ - Newszacks.com·31d ago·Negative
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
View source ↗ - Newsbenzinga.com·31d ago·Negative
Xenon Stock Reaction Is Overblown: Analyst Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.
View source ↗ - Newsbarrons.com·31d ago·Negative
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
View source ↗ - Newsreuters.com·32d ago·Negative
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major depression and bipolar disorder, following reports of mental and nervous system-related side effects.
View source ↗ - Newsglobenewswire.com·32d ago·Negative
…ocal Seizures and Provides Update on Psychiatry Clinical Program VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Xenon to Present at Wells Fargo Healthcare Conference VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…ta and Rational Polytherapy Potential for Azetukalner at EEC 2026 VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.
View source ↗
Earnings
Mon, Nov 2(in 13 days)
Consensus estimate $-1.13 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.11 vs $-1.14beat
- Thu, May 7$-1.17 vs $-1.17beat
- Thu, Feb 26$-1.31 vs $-1.20miss
- Mon, Nov 3$-1.15 vs $-1.16beat
- Mon, Aug 11$-1.07 vs $-1.03miss
- Mon, May 12$-0.83 vs $-0.94beat
Estimates and results for XENE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XENE officers and directors.
- Bought
- $1.7m
- Sold
- $22.0m
2 trades
26 trades
- Kelly Thomas Patrickbought
- Mortimer Ianbought
- Kenney Christopher Johnsold
- Kenney Christopher Johnsold
- Gannon Stevensold
- Patou Garysold
- Cannon Gilliansold
- Kenney Christopher Johnsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XENE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.